Tranexamic acid inhibits fibrinolysis by competitively blocking the lysine binding sites of plasminogen, inhibiting binding between fibrin and plasminogen, and activation of plasminogen. It also competitively inhibits tissue plasminogen activator and inhibits plasmininduced platelet activation. The synthesis of tranexamic acid was first reported in 1962. It is used to treat or prevent excessive blood loss from trauma, surgery, and in various medical conditions including haemophilia and heavy menstrual bleeding. As a medicine affecting coagulation, it is listed in the World Health Organization’s List of Essential Medicines. Tranexamic acid remains a versatile and inexpensive agent with potential benefit in health services from the lowest to highest income countries. This pharmacy review focuses on the evidence base to support the use of tranexamic acid in acquired and inherited bleeding disorders to reduce bleeding complications.
1. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41-7.
2. Wikipedia. Tranexamic acid. Available from: https://en.wikipedia.org/wiki/Tranexamic_acid (accessed 18 March 2016).
3. Grassin-Delyle S, Tremey B, Abe E, et al. Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2013;111:916-24.
4. Pfizer Ltd. Cyclokapron injection. 5.1 Pharmacodynamic properties. March 2016. Available from: www.medicines.org.uk/emc/medicine/1489#PHARMACODYNAMIC_PROPS (accessed 18 March 2016).
5. Wesley MC, Pereira LM, Scharp LA, et al. Pharmacokinetics of tranexamic acid in neonates, infants, and children undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 2015;122:746-58.
6. Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia 2015;70 Suppl 1:50-3, e18.
7. Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther 2015;47:339-50.
8. Sperzel M, Huetter J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost 2007;5:2113-8.
9. Rea CJ, Foley JH, Bevan DH, et al. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. Ann Hematol 2014;93:683-92.
10. Tran HT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2014;20:369-75.
11. PharmLine Uganda. Tranexamic acid. Available from: http://www.pharmlineug.com/search.php?drug=Tranexamic%20Acid (accessed 22 March 2016).
12. MedIndia. Drug “tranexamic acid” price list. Available from: http://www.medindia.net/drug-price/tranexamic-acid.htm (accessed 22 March 2016).
13. Pfizer Ltd. Cyclokapron injection. 6. Pharmaceutical particulars. March 2016. Available from: www.medicines.org.uk/emc/medicine/1489#PHARMACEUTICAL_PARTS (accessed 22 March 2016).
14. Pfizer, Pharmacia & Upjohn. Cyclokapron label. December 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/019281s033lbl.pdf (accessed 22 March 2016).
15. de Guzman R, Polykratis IA, Sondeen JL, et al. Stability of tranexamic acid after 12-week storage at temperatures from -20°c to 50°c. Prehosp Emerg Care 2013;17:394-400.
16. Ferring Pharmaceuticals. Lysteda prescribing information. October 2013. Available from: www.lysteda.com/assets/pi_ferring2013-1f2d77bcb42b5738c55afab5280d7e9c.pdf (accessed 22 March 2016).
17. Pfizer Ltd. Cyclokapron tablets. February 2014. Available from: www. medicines.org.uk/emc/medicine/16512 (accessed 22 March 2016).
18. MedIndia. Tranexamic acid - drug information. Available from: www.medindia.net/doctors/drug_information/tranexamic_acid.htm (accessed 22 March 2016).
19. Thall Bastow BD. Teratology and drug use during pregnancy. Medscape. 2016. Available from: http://emedicine.medscape.com/article/260725- overview#a5 (accessed 21 April 2016).
20. Gilad O, Merlob P, Stahl B, et al. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med 2014;9:407-10.
21. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2nd ed. 2012. Available from: www1.wfh.org/publications/files/pdf-1472.pdf (accessed 23 March 2016).
22. van Galen KPM, Engelen ET, Mauser-Bunschoten EP, et al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database of Systematic Reviews 2015, issue 12, art. no.: CD011385. doi:
23. Forbes CD, Barr RD, Reid G, et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J 1972;2:311-3.
24. Lee AP, Boyle CA, Savidge GF, et al. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005;198:33-8.
25. Nuvvula S, Gaddam KR, Kamatham R. Efficacy of tranexamic acid mouthwash as an alternative for factor replacement in gingival bleeding during dental scaling in cases of hemophilia: a randomized clinical trial. Contemp Clin Dent 2014;5:49-53.
26. Federici AB, Sacco R, Stabile F, et al. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 2000;6:71-7.
27. Franchini M, Rossetti G, Tagliaferri A, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years’ experience in three Italian hemophilia centers. Haemophilia 2005;11:504-9.
28. Frachon X, Pommereuil M, Berthier AM, et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:270-5.
29. Givol N, Hirschhorn A, Lubetsky A, et al. Oral surgery-associated postoperative bleeding in haemophilia patients - a tertiary centre’s two decade experience. Haemophilia 2015;21:234-40.
30. Zanon E, Martinelli F, Bacci C, et al. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia 2000;6:533-6.
31. Nickles K, Wohlfeil M, Alesci S, et al. Comprehensive treatment of periodontitis in patients with von Willebrand disease. J Periodontol 2010;81:1432-40.
32. Hewson I, Makhmalbaf P, Street A, et al. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia 2011;17:e185-8.
33. Coppola A, Windyga J, Tufano A, et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database of Systematic Reviews 2015, issue 2, art. no.: CD009961. doi:
34. Valentino LA, Holme PA. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly? Haemophilia 2015;21:709-14.
35. Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia 2012;18:544-9.
36. Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia 2015;21:374-9.
37. Rossi M, Jayaram R, Sayeed R. Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes? Interact Cardiovasc Thorac Surg 2011;13:320-31.
38. Siboni SM, Biguzzi E, Pasta G, et al. Management of orthopaedic surgery in rare bleeding disorders. Haemophilia 2014;20:693-701.
39. Siboni SM, Biguzzi E, Solimeno LP, et al. Orthopaedic surgery in patients with von Willebrand disease. Haemophilia 2014;20:133-40.
40. Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009;102:487-92.
41. Sarris I, Arafa A, Konaris L, et al. Topical use of tranexamic acid to control perioperative local bleeding in gynaecology patients with clotting disorders: two cases. Haemophilia 2007;13:115-6.
42. Yilmaz D, Akin M, Ay Y, et al. A single centre experience in circumcision of haemophilia patients: Izmir protocol. Haemophilia 2010;16:888-91.
43. Davis A, Walsh M, McCarthy P, et al. Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study. Haemophilia 2013;19:583-9.
44. Ragni MV, Machin N, Malec LM, et al. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia 2016 Feb 4. doi:
45. Chi C, Pollard D, Tuddenham EG, Kadir RA. Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 2010;23:215-22.
46. Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin. Haemophilia 2008;14 Suppl 1:21-30.
47. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212-20.
48. European Medicines Agency. Assessment report. Antifibrinolytics containing aprotinin, aminocaproic acid and tranexamic acid. Tranexamic acid. EMA/680967/2012. October 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Antifibrinolytic_medicines/WC500153603.pdf (accessed 21 April 2016).
49. Lecker I, Wang DS, Whissell PD, et al. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol 2016;79:18-26.
50. Okamoto S, Okamoto U. Amino-methyl-cyclohexane carboxylic acid: AMCHA. A new potent inhibitor of fibrinolysis. Keio J Med 1962;11:105-15. Available from: https://www.jstage.jst.go.jp/article/kjm1952/11/3/11_3_105/_pdf (accessed 21 April 2016).